Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several weeks. His confirmation was contentious, his vision unconventional, and now, the early moves of his leadership suggest that we’re in for a major recalibration. Though not a key legislative priority, the transformation of certain areas in America’s health care apparatus has clearly begun, and its implications could reshape how we think about health for years to come.
The Great Reshuffling
RFK Jr’s tenure began with a continuation of what we’ve been experiencing in other federal agencies—a mass exodus. The Department of Government Efficiency (DOGE) initiated widespread layoffs across HHS agencies, leading to significant workforce disruption. However, the US Food and Drug Administration (FDA) recently had to reinstate about 180 medical division employees.1
This reversal came after industry leaders pointed out these positions were funded by user fees, not taxpayer dollars, as part of FDA funding is through the Prescription Drug User Fee Act (PDUFA) program.2 The absence of medical division employees would cripple critical safety reviews for medical devices and pharmaceuticals.
Established by Congress in 1992, PDUFA created a system where pharmaceutical manufacturers pay fees to support faster FDA review and approval of their drug products. These user fees now fund a substantial portion of FDA operations, though determining exactly which positions are directly supported by these funds isn’t straightforward. PDUFA must be reauthorized every 5 years and is currently renewed through September 2027.3
The recent employee reinstatements suggest that the initial layoffs may have threatened the FDA’s ability to meet these requirements and maintain its review timelines for new drugs and devices.
New Direction, New Priorities
Amid this staffing turnover, we’re starting to see RFK Jr’s broader vision for health care take shape: his “Make America Healthy Again” agenda is an unconventional departure from the traditional pharmaceutical-driven approach. Instead, his administration is prioritizing disease prevention, alternative medicine, and lifestyle-based interventions. Which, don’t get me wrong, is an important priority, but fails to acknowledge decades of scientific evidence demonstrating the undeniable efficacy of pharmaceutical interventions.1
The American health care system stands at a crossroads. RFK Jr’s emphasis on prevention over treatment represents more than a simple policy shift—it’s a fundamental reimagining of how we approach health and wellness. However, this transformation must be balanced against maintaining essential services and protecting public health.
The push toward preventative care and alternative treatments creates new opportunities, but also new challenges. How will these changes affect Medicare drug price negotiations? What happens to the existing pharmaceutical development pipeline? Can alternative medicine integrate effectively with conventional health care delivery systems?
The health care system we know is changing. Whether that change leads to improved health outcomes or increased challenges remains to be seen. What's certain is that providers, patients, and industry players all need to prepare for a very different health care landscape in the years ahead.
Join me every Wednesday as I highlight key court decisions, review notable health policies, and analyze what's behind the bill in health care.
References
1. Inside RFK Jr.'s health department takeover. Politico. Published February 22, 2025. Accessed February 25, 2025. https://www.politico.com/news/2025/02/22/rfk-hhs-first-week-vaccine-advisers-workforce-00205596
2. F.D.A. Reinstates Fired Medical Device, Food and Legal Staffers. The New York Times. Published February 24, 2025. Accessed February 25, 2025. https://www.nytimes.com/2025/02/24/science/fda-safety-workers-reinstated.html
3. US Food and Drug Administration. Prescription Drug User Fee Amendments. Updated December 18, 2024. Accessed February 25, 2025. https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments
